

02 November 2022



Year-to-date and Q3 2022 Results

Conference call and webcast for investors and analysts

Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for the full year (FY) 2021 and any impacts of the COVID-19 pandemic. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in our third quarter 2022 earnings release and Annual Report on Form 20-F for FY 2021.

All outlooks, ambitions, and considerations should be read together with pages 5-7 of the stock-exchange announcement relating to an update to investors dated 23 June 2021, paragraph 19 of Part 7 of the Circular to shareholders relating to the demerger of Haleon plc dated 1 June 2022 and the Guidance, assumptions and cautionary statements in the Q3 2022 earnings release.

Basis of preparation: GSK satisfied the formal criteria according to IFRS 5 for treating Consumer Healthcare as a 'Discontinued operation' effective from 30 June 2022. On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. The amounts presented in this presentation for continuing operations and Adjusted results excludes the Consumer Healthcare business discontinued operation. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.

Agenda

Year-to-date and Q3 2022

Emma Walmsley

Innovation

Dr Tony Wood

Performance

Luke Miels, Deborah Waterhouse and Iain Mackay

Trust

Emma Walmsley

Q&A

David Redfern



Year-to-date and Q3 2022 Delivering a landmark year

Emma Walmsley, Chief Executive Officer

Year-to-date 2022

Delivering a landmark year

Double-digit turnover and adj. operating profit growth

Strong commercial execution with growth³ across the portfolio:

- Specialty Medicines +49% (+13% excl. Xevudy)
- Vaccines +12% (+20% excl. pandemic adjuvant)
- General Medicines +2%
- COVID-19 solutions sales of £2.2bn

R&D investment and strategic business development support future growth

Absolute values at actual exchange rates (AER); changes at CER and year-to-date (YTD) or nine months (9M), unless stated otherwise. 1. Continuing results represents performance excluding discontinued operations, 2. Excluding COVID-19 solutions, 3. At CER; see Appendix slide 31 for continuing operations basis of guidance.

Turnover¹
+19%

£21.9bn

Adj. operating profit¹
+16%

£6.6bn

Adj. EPS¹
+20%

113.9p

Free cash flow¹

£2.5bn

Full-year 2022 guidance^{2,3} again increased

Sales growth: 8-10%

Adj. operating profit growth: 15-17%

Adj. EPS: growth c.1% below Adj. OP

Q3 2022

Sales growth +9%¹ (+7%²)

Improving revenue mix, with prioritised investment in growth and disciplined cost control, supports confidence in delivering medium-term outlooks

- Specialty Medicines: growth across all therapy areas
- Vaccines: another record *Shingrix* quarter (£760m)
- General Medicines: antibiotics market recovery; *Trelegy* growth in respiratory
- Adj. SG&A: targeted launch investment in *Shingrix* and Specialty
- Adj. R&D: increased investment across Vaccines and Specialty pipeline

Absolute values at actual exchange rates (AER); changes at CER in Q3 or third quarter, unless stated otherwise. 1. Continuing results represents performance excluding discontinued operations, 2. Excluding COVID-19 solutions; see Appendix slide 31 for continuing operations basis of guidance.

Turnover¹

+9%

£7.8bn

Adj. operating profit¹

+4%

£2.6bn

Adj. EPS¹

+11%

46.9p

Cash flow from operations¹

£1.9bn

Year-to-date 2022: late-stage R&D pipeline momentum

Pipeline

Potential best-in-class profile for novel RSV-OA¹ candidate vaccine:

- **94.1%** reduction in severe RSV disease in older adults
- **82.6%** overall vaccine efficacy in older adults
- Favourable safety profile

Regulatory approvals and submission acceptance Q3 2022 - *Menveo* (US)²; *Boostrix* (US)³, *Mosquirix*⁴ plus regulatory submission acceptances for RSV-OA (US⁵, EU, JP) and *Apretude* (EU)

Q2 2022 - *Priorix* for MMR (US)⁶, *Vocabria* plus rilpivirine (JP)⁷, *Cervarix* (CN)⁸

Q1 2022 - *Cabenuva* (US)⁹, *Triumeq* PD (US)¹⁰, *Benlysta* (CN)¹¹, and *Covifenz* (CA)¹²

News flow

H2 2022 - anticipated late-stage readouts MenABCWY vaccine, gepotidacin (EAGLE), *Jemperli* (RUBY)



Strategic business development

Acquisition of Affinivax, Inc.

- Completed 15 August 2022
- Access to disruptive MAPS¹³ technology
- AFX3772, phase II next-generation 24-valent pneumococcal vaccine
- 30+ valent pre-clinical vaccine candidate

Acquisition of Sierra Oncology, Inc.

- Completed 1 July 2022
- Momelotinib is a potential new treatment for myelofibrosis patients with anaemia
- US FDA regulatory submission acceptance in Q3 2022

Licence agreement with Spero Therapeutics LLC¹⁴

- Exclusive access to tebipenem HBr¹⁵, a late-stage antibiotic that may treat complicated urinary tract infections

1. Respiratory syncytial virus in older adults, 2. US FDA approval of a new single-vial presentation, 3. US FDA approval for immunisation during pregnancy, 4. WHO grants prequalification to *Mosquirix*, 5. Priority Review action date 3 May 2023, 6. US FDA approval for the prevention of measles, mumps and rubella, 7. Approval by Japan's Ministry of Health, Labour and Welfare for *Vocabria* used in combination with rilpivirine for human immunodeficiency virus, 8. China vaccine approval for certain types of cancer-causing human papillomavirus, 9. US FDA approval of *Cabenuva* for use every two months, 10. US FDA approval of *Triumeq* PD, the first dispersible single tablet regimen for children living with HIV, 11. China's National Medical Products Administration approved *Benlysta* for lupus nephritis, 12. Health Canada's approval of *Covifenz*, an adjuvanted plant-based COVID-19 vaccine, 13. Multiple Antigen Presenting System, 14. Subject to customary closing conditions, including expiration of waiting period under Hart-Scott-Rodino. 15. Tebipenem pivoxil hydrobromide.



Innovation

Dr Tony Wood

A focused biopharma company

Uniting science, technology and talent to get ahead of disease together

Science of the immune system, human genetics and advanced technologies

Execution

Focus on pipeline acceleration and complementary business development to deliver innovative vaccines and medicines

Technology


Using platform and data technology to deliver innovative vaccines and medicines

Culture

Building a culture that is ambitious for patients; attracting top talent and highly skilled specialists


Innovation: four focused therapeutic areas

Two thirds of our development portfolio comes from infectious disease and HIV




Infectious Diseases

RSV OA¹
MenABCWY
bepirovirsen
gepotidacin
tebipenem
Pneumococcal 24-valent
mRNA influenza



HIV

Apretude
N6LS (bNAb)²
3rd generation INSTI³
Capsid inhibitor



Immunology/ Respiratory

depemokimab
Nucala (COPD)⁴
GSK4532990 (NASH)⁵



Oncology

mometinib
Jemperli
cobolimab
CD226 axis

Strategic business development

Note: select pipeline programmes shown (see slide 28 for comprehensive list of pipeline projects). 1. Respiratory syncytial virus in older adults, 2. Broadly neutralising antibody, 3. Integrase strand transfer inhibitor, 4. Chronic obstructive pulmonary disease, 5. Non-alcoholic steatohepatitis.

Innovation: potential best-in-class RSV vaccine in the most vulnerable adults

Demonstrated consistent and sustained high efficacy

Reduction in severe disease¹

94.1%

Efficacy in those with comorbidities²

94.6%

Efficacy in those aged 70-79 years³

93.8%

Key risk factors are age and comorbidities

- Older adults at increased risk from RSV disease due to reduced immune function
- Those with comorbidities, e.g., cardiovascular, respiratory, and diabetes, are at even higher risk of severe outcomes¹
- CDC: >90% of hospitalised adults have underlying medical conditions (c.50%: 3+)⁴
- RSV has substantial economic burden with direct medical costs c.\$3bn⁵ in US alone⁶

Source; Ison, IDWeek 2022. 1. Severe confirmed RSV-Lower Respiratory Tract Disease (LRTD) VE 94.1% (95% CI 62.4-99.9), 2. LRTD in subjects with ≥ 1 comorbidity of interest VE=94.6% CI 65.9-99.9), 3. RSV LRTD VE 93.8% (CI 60.2-99.9), 4. Introduction to ACIP's Adult Respiratory Syncytial Virus Work Group: <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-22-23/01-RSV-Kotton-508.pdf>, 5. Herring, W. et al. (2021), Carrico, J et al (2022); 6. Additional impact from lost productivity, long-term health consequences and care costs. Note: Comorbidities included in '006 study included those with pre-existing chronic conditions such as chronic obstructive pulmonary disease, asthma, any chronic respiratory/pulmonary disease, chronic heart failure, diabetes mellitus type-1 or type-2 and advanced liver or renal disease. Around 39% of participants in both the placebo and the vaccine groups had these pre-existing comorbidities.

Innovation: scientific momentum

Advancing the next-generation of potential new vaccines and medicines

Infectious Disease

- *Shingrix* data at IDWeek 2022 showed sustained protection of up to 10 years after vaccination

Immunology / Respiratory

- Bepirovirsen B-CLEAR end of treatment data expected at AASLD 2022
- Otilimab ContrRAst phase III programme demonstrated limited efficacy

HIV


- Positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb)

Oncology

- Positive *Jemperli* PERLA phase II; data expected at ESMO IO 2022
- Cobolimab COSTAR Lung progresses to phase III

Opportunity Driven

- AdCom voted in favor of daprodustat as a potential new medicine for dialysis dependent patients



Innovation: 2022-2023 key news flow

Regulatory approvals or other regulatory action	Achieved	<p><i>Priorix</i> - MMR¹ (US) <i>Vocabria/Rekambys</i> - HIV (JP) <i>Cervarix</i> - human papillomavirus (CN⁴) <i>Covifenz</i>² - COVID-19 vaccine (CA³) <i>Menveo liquid</i> (US) <i>Boostrix</i> (US) <i>Benlysta</i> - Lupus nephritis (CN) <i>Juluca</i> - HIV (CN)</p>	H1 2023	<p>daprodustat - ASCEND, anaemia of CKD (US, EU) momelotinib - MOMENTUM, myelofibrosis (US) RSV older adults vaccine - AReSVi-006 (US) SKYCovione COVID-19 vaccine (EU⁷) <i>Shingrix</i> - 18+ at increased risk of HZ⁵ (JP)</p>
	H2 2022	<p>Rotarix Liquid (US) COVID-19 (Sanofi) vaccine (EU)</p>	H2	<p><i>Blenrep</i> - DREAMM-3, 3L+ MM (US, EU) <i>Jemperli</i>¹² - RUBY¹⁰, 1L endometrial cancer (US) RSV older adults vaccine - AReSVi-006 (EU, JP) cabotegravir (long-acting) pre-exposure prophylaxis (EU)</p>
Regulatory submissions or acceptances	Achieved	<p><i>Shingrix</i> - 18+ at increased risk of HZ⁵ (JP) daprodustat - ASCEND, anaemia of CKD⁶ (US, EU) momelotinib - MOMENTUM, myelofibrosis (US) COVID-19 (Sanofi) vaccine (EU) SKYCovione COVID-19 vaccine (EU⁷) RSV older adults vaccine - AReSVi-006 (US, EU, JP) cabotegravir (long-acting) pre-exposure prophylaxis (EU)</p>	H1 2023	<p><i>Jemperli</i>¹² - RUBY¹⁰, 1L endometrial cancer (US, EU) MenABCWY vaccine (US) mepolizumab - severe asthma (CN) COVID-19 (Sanofi) vaccine (US) gepotidacin - EAGLE¹⁰, uUTI (US)</p>
	H2 2022	<p><i>Blenrep</i> - DREAMM-3, 3L+ MM⁸ (US, EU) momelotinib - MOMENTUM, myelofibrosis (EU)</p>	H2	<p><i>Blenrep</i> - DREAMM-8, 2L+ MM (US, EU) <i>Blenrep</i> - DREAMM-7, 2L+ MM (US, EU) mepolizumab - nasal polyposis (CN, JP)</p>
Late-stage readouts ⁹	Achieved	<p><u>Phase III</u> RSV older adults vaccine - AReSVi-006 COVID-19 (Sanofi) vaccine SKYCovione COVID-19 vaccine</p>	H1 2023	<p><u>Phase III</u> <i>Blenrep</i> - DREAMM-8, 2L+ MM <i>Blenrep</i> - DREAMM-7, 2L+ MM</p>
	H2 2022	<p>gepotidacin - EAGLE¹⁰, uUTI¹¹ <i>Jemperli</i>¹² - RUBY¹⁰, 1L endometrial cancer <i>Blenrep</i> - DREAMM-3, 3L+ MM MenABCWY vaccine</p>	H2	<p>lineroxibat - cholestatic pruritus in PBC¹⁵ <i>Zejula</i>¹² - FIRST, 1L maintenance OC¹⁶</p>
	Achieved	<p><u>Phase II</u> bepirovirsen - B-CLEAR, HBV¹³ <i>Jemperli</i>¹² - PERLA, NSCLC¹⁴</p>	H1 2023	<p><u>Phase II</u> bepirovirsen - B-TOGETHER, HBV MenABCWY vaccine 2nd gen</p>
			H2	<p><i>S. Aureus</i> vaccine</p>

1. Measles, mumps, and rubella, 2. Partnered with Medicago, Inc., 3. Canada, 4. China, 5. Herpes Zoster 6. Chronic Kidney disease, 7. Received regulatory approval in South Korea, 8. Multiple myeloma, 9. Late-stage is defined as Phase IIb onwards, 10. Interim analysis, 11. Uncomplicated urinary tract infection, 12. Tesaro asset, 13. Hepatitis B virus, 14. Non-small cell lung cancer, 15. Primary biliary cholangitis, 16. Ovarian cancer.



Performance: growth drivers


Luke Miels, Chief Commercial Officer

Deborah Waterhouse, CEO, ViiV Healthcare

Performance: Q3 2022 turnover £7.8bn, +9%

Strong commercial execution across all product groups

- **Specialty Medicines:** strong demand for *Benlysta*, *Nucala* and new HIV products. Continued Oncology progress
- **Vaccines:** Broad-based *Shingrix* demand growth, with new launches and strong commercial execution
- **General Medicines:** *Trelegy* growth and antibiotic market recovery more than offset generic competition and RAR¹ drag
- **Pandemic:** *Xevudy* International contract delivery (contributed 2 percentage points of sales growth)




Absolute values at AER; changes at CER and for Q3, unless stated otherwise; 1>Returns and rebates.

Performance: Vaccines +9%¹; Shingrix delivers record performance

Q3 2022: £760m Shingrix sales

- **US:** higher retail and non-retail demand, partly offset by unfavourable wholesaler inventory movements
- **EU and International:** 38% of Q3 sales; post-pandemic rebound, new launches and strong commercial execution
- **Unconstrained supply:** available in 25 countries with two new launches in Q3, on track for >35 countries by 2024
- **2022 outlook:** record year of sales, with strong double-digit growth. Confident in ambition to double *Shingrix* sales by 2026²




Absolute values at AER; changes at CER and for Q3, unless stated otherwise. 1. Excluding pandemic vaccines sales, 2. Ambition uses 2020 as the base year.

Performance: HIV¹ momentum driven by innovation sales

Growth led by *Dovato* and LA² regimens

- Sales: YTD 2022 +9%; Q3 2022 +7%
- Innovation portfolio: >40% sales, reflecting increased confidence in *Dovato* and LA injectable regimens
- *Dovato*: £360m, +60%; now ~25% of HIV sales
- *Cabenuva*: >£100m in sales; strong patient demand
- *Apretude*: file submitted with EU; world's first LA injectable for PrEP³ of HIV, dosed every two months
- N6LS: positive PoC⁴ data presented at HIV Glasgow



Absolute values at AER; changes at CER for Q3 and YTD, unless stated otherwise. 1. Human immunodeficiency virus, 2. Long-acting, 3. Pre-exposure prophylaxis is the use of medications to prevent the spread of disease. 4. Proof of concept



Performance: financial results

Iain Mackay, Chief Financial Officer

Performance: Q3 2022 results and total to adjusted reconciliation

	Turnover (£bn)	Operating profit (£bn)	Q3 2022 EPS (pence)	Q3 2021 EPS (pence)
Total results - Total			255.9	29.2
Profit from discontinued operations			(237.1)	(7.3)
Total results - Continuing operations	7.8	1.2	18.8	21.9
Intangible amortisation		0.2	3.9	3.9
Intangible impairment		<0.1	0.4	5.0
Major restructuring		0.1	1.4	1.9
Transaction related		0.7	12.2	5.1
Divestments, Significant Legal and other		0.4	10.2	(0.4)
Adjusted results	7.8	2.6	46.9	37.4

Key dynamics

Profit from discontinued operations

- ⬆️ Gain on demerger (fair value less book value)
- ⬆️ Gain on retained stake on demerger (fair value less book value)

Transaction related

- ⬇️ ViiV contingent consideration liability movements (majority FX¹)

Divestments, Significant Legal and other

- ⬇️ Fair value mark to market loss on the retained stake in Haleon

Turnover: £7.8bn², 18% at AER, +9% at CER


Adj. OP³: £2.6bn², +18% at AER, +4% at CER

Adj. EPS: 46.9p², +25% at AER, +11% at CER

Table may not sum due to rounding. See page 18 of GSK's third quarter 2022 earnings release for a full reconciliation. 1. Foreign exchange; 2. Continuing results represents performance excluding discontinued operations; 3. Operating profit

Performance: Q3 2022 adjusted operating margin

Stable margin of 33.3%, at AER



Key dynamics

- ⬆ Sales: growth across all product groups
- ⬆ COGS: increasing Specialty Medicines and Vaccines mix (65% vs 62%)
- ⬆ SG&A: continued restructuring benefits and exchange gains on Vir² collaboration profit share
- ⬆ R&D: completion of several late-stage clinical development programmes which incurred costs in Q3 2021
- ⬆ Royalties: Biktarvy and higher Gardasil
- ⬇ COGS: pandemic sales mix; increased supply chain costs
- ⬇ SG&A: increased launch investment in Specialty Medicines and *Shingrix*; freight and distribution cost increases
- ⬇ R&D: increased Vaccines clinical development investment, including mRNA, MAPS³; late-stage Specialty Medicines; early-stage programmes

1. Excluding COVID-19 solutions; 2. Vir Biotechnology, Inc; 3. Multiple Antigen Presenting System

Performance: Q3 2022 adj. operating profit to net income¹

	Q3 2021 £m	Q3 2022 £m	Key commentary
Operating profit	2,209	2,605	+18% at AER, +4% at CER
Net finance expense	(190)	(177)	Increased interest income from higher interest rates and larger cash balances following the demerger
Share of associates	3	(1)	
Tax	(402)	(402)	
Tax rate	19.9%	16.6%	Reflects timing of settlements with various tax authorities
Non-controlling interests	(121)	(135)	Increased allocation of ViiV profits
Net income	1,499	1,890	+26% at AER, +11% at CER

1. GSK continuing operations only


Performance: Year-to-date 2022 free cash flow of £2.5bn¹

Year-to-date 2022 cash generated from operations of £5.8bn¹

Key dynamics

Higher cash generated from operations, including:

- ↑ - Increased adjusted operating profit
- ↑ - Upfront income from Gilead Science, Inc. settlement
- ↑ - Favourable foreign exchange
- ↑ - Favourable timing of collections
- ↓ - Unfavourable timing of profit share payments for *Xevudy* sales
- ↓ - Increased cash contributions to pensions
- ↓ - Increased contingent consideration payments
- ↓ Higher taxation payments
- ↑ Lower net Capex, with reduced purchases of intangibles



1. GSK continuing operations only; 2. Cash generated from operations, including changes in working capital, Significant Legal payments and operating CCL; 3. Net Capex includes purchases less disposals of property, plant and equipment and intangibles; 4. Other includes net interest paid, income from associates and JVs and Non-Controlling Interests.

Performance: increasing guidance for sales and adj. operating profit

Strong Q3 2022 and year-to-date performance

YTD 2022 performance

Sales¹
10% growth to £19.8bn

Adj. OP¹
16% growth to £6.2bn

Adj. earnings per share¹
20% growth to 105.7p

COVID-19 solutions
£2.2bn sales of *Xevudy* and negligible pandemic adjuvant

2022 guidance

Sales¹
Between 8% to 10% growth
Previous: between 6% to 8% growth

Adj. OP¹
Between 15% to 17% growth
Previous: between 13% to 15% growth

Adj. earnings per share
Growth around 1% below adj. OP¹

COVID-19 solutions:
The majority of expected COVID-19 solutions sales for 2022 have been achieved in the year-to-date. We now expect this to reduce overall adj. OP growth by around 4 percentage points.

1. Excluding COVID-19 solutions and at CER. Please also refer to page 2 of the third quarter 2022 results announcement. All outlooks, targets, ambitions and expectations regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on page 67 of our third quarter 2022 earnings release. See Appendix slide 31 for continuing operations basis of guidance.



Trust: delivering health impact sustainably

Emma Walmsley, Chief Executive Officer

Purpose: to get ahead of disease together

For health impact, shareholder returns and thriving people

Building trust

Launched Sustainable Procurement Programme for suppliers to support climate and nature goals

Achieved leadership ranking in S&P Corporate Sustainability Assessment

Granted WHO prequalification for first approved malaria vaccine

**Ambition to positively impact the health of
2.5 billion people over the next 10 years**

Q & A

Appendix

Innovation: 65 potential new vaccines and medicines

Phase I

2904545* (recombinant protein) ¹ <i>C. difficile</i>
4429016* (bioconjugated, recombinant protein) ¹ <i>K. pneumoniae</i>
3993129 (recombinant subunit) ¹ CMV
4382276* (mRNA) flu
4396687* (mRNA) COVID-19
4077164* (bivalent GMMA) iNTS (<i>Typhimurium</i> + <i>Enteritidis</i>)**
3943104* (recombinant protein) ¹ Therapeutic HSV
4106647* (protein-adjuvant) ¹ HPV ¹
BVL-GSK098* (ethionamide booster) tuberculosis
VIR-2482* (neutralizing monoclonal antibody) [^] influenza
2556286* (Mtb inhibitor) tuberculosis
3186899* (CRK-12 inhibitor) visceral leishmaniasis ²
3494245* (protease inhibitor) visceral leishmaniasis
3772701* (<i>P. falciparum</i> whole cell inhibitor) malaria
3882347* (FimH antagonist) uUTI
3923868 (PI4kβ inhibitor) viral COPD exacerbations
4182137* (VIR-7832 monoclonal antibody) COVID-19 ¹
3965193 (PAPD5/7 inhibitor) HBV
3739937 (maturation inhibitor) HIV
cabotegravir (400 mg/ml formulation) HIV
4004280 (capsid protein inhibitor) HIV
4011499 (capsid protein inhibitor) HIV
3745417 (STING agonist) cancer
4074386* (anti-LAG3) cancer
6097608 (anti-CD96) cancer
4381562* (anti-PVRIG) cancer
4527226* (AL101, anti-sortilin) neurodegenerative diseases
3858279* (anti-CCL17) osteoarthritis pain
3915393* (TG2 inhibitor) celiac disease
1070806 (anti-IL18) atopic dermatitis
3888130* (anti-IL7) multiple sclerosis

Phase II

3437949* (recombinant protein) ¹ Malaria fractional dose
3878858* (bioconjugated, recombinant protein) ¹ <i>S. aureus</i> ³
4069327* (bioconjugated, tetravalent) <i>Shigella</i> **
3528869* (viral vector with recombinant protein) ¹ Therapeutic HBV ¹
4023393 (conjugated, recombinant protein) MenABCWY 2 nd gen ¹
4178116 (live, attenuated) Varicella new strain
5101955* (MAPS) Pneumococcal 24-Valent - Paediatric
5101956* (MAPS) Pneumococcal 24-Valent - Adults
bepirovirsen* (HBV ASO) HBV
3036656* (leucyl t-RNA inhibitor) tuberculosis
sanfetrinem cilxetil* (serine beta lactamase inhibitor) tuberculosis
3640254 (maturation inhibitor) HIV
3810109* (broadly neutralizing antibody) HIV
4428859* (anti-TIGIT) cancer
4532990* (HSD17B13 siRNA) non-alcoholic steatohepatitis ⁴

Phase III/Registration

Bexsero infants US (recombinant protein) MenB
Covifenz (Medicago)* COVID-19 ^{††}
4353001 (Sanofi)* COVID-19 ^{††}
SKYCovione (SK Bioscience)* COVID-19 ^{††}
3536819 (conjugated, recombinant protein) MenABCWY 1 st gen
Rotarix liquid US (live attenuated, PCV free) rotavirus
3844766* (recombinant protein) ¹ RSV older adults
gepotidacin* (BTI inhibitor) uUTI and GC
Xevudy* (sotrovimab/VIR-7831 monoclonal antibody) COVID-19
Blenrep* (anti-BCMA ADC) multiple myeloma
Jemperli* (anti-PD-1) 1L endometrial cancer**
Zejula* (PARP inhibitor) ovarian, lung and breast cancer
momelotinib* (JAK1, JAK2 and ACVR1 inhibitor) myelofibrosis
cobolimab* (anti-TIM-3) NSCLC
latozinemab* (AL001, anti-sortilin) frontotemporal dementia***
depemokimab* (LA anti- IL5) asthma**
Nucala (anti-IL5) COPD
daprodustat (HIF-PHI) anaemia of chronic kidney disease
linerixibat (IBAT inhibitor) cholestatic pruritus in primary biliary cholangitis







- Infectious Diseases
- HIV (ViiV)
- Oncology
- Immunology/Respiratory
- Opportunity Driven

Note: Only the most advanced indications are shown for each asset




*In-license or other alliance relationship with third party; **Additional indications or candidates also under investigation; † adjuvanted; †† GSK contributing pandemic adjuvant ^GSK has exclusive option to co-develop post Ph2. 1. In Phase 1/2 study 2. Transition activities underway to enable further progression by partner 3. In potentially registration Ph2 trial 4. Ph3 trial in patients with progranulin gene mutation. 4. Imminent Phase 2 start CMV: Cytomegalovirus; GMMA: Generalized Modules for Membrane Antigens; TCV: Typhoid conjugate vaccine; iNTS: invasive non-typhoidal salmonella; HSV: Herpes simplex virus; HPV: Human papillomavirus; uUTI: uncomplicated urinary tract infection; COPD: chronic obstructive pulmonary disease; siRNA: small interfering RNA; HBV: Hepatitis B virus; ASO: antisense oligonucleotide; MAPS: Multiple Antigen Presenting System; TCR T: T-cell receptor therapy; NSCLC: non-small cell lung cancer; MenB: Meningitis B; PCV: Porcine circovirus; RSV: Respiratory syncytial virus; GC: gonorrhoea; ADC: antibody drug conjugate; SS: synovial sarcoma; MRCLS: myxoid/round cell liposarcoma; LA: long-acting

Innovation: R&D pipeline changes since last quarter




Phase I

-  **GSK3772701** (*P falciparum* whole cell inhibitor) malaria
-  **GSK4106647A** (protein adjuvant) HPV
-  **GSK4362676** (Mat2A) cancer
-  **GSK3845097** (NY-ESO-1/dnTGFb TCR T) cancer
-  **GSK3901961** (NY-ESO-1/CD8a TCR T) cancer
-  **GSK3884464** heart failure


Phase II

-  **GSK5101955A** (MAPS) Pneumococcal 24-Valent – Paediatric
-  **GSK5101956A** (MAPS) Pneumococcal 24-Valent – Adults
-  **GSK4428859** (anti-TIGIT) cancer




Phase III

-  **cobolimab** (anti-TIM-3) NSCLC
-  **letetresgene-autoleucel** (NY-ESO-1 TCR) SS/MRCLS3
-  **otilimab** (anti-GM-CSF) rheumatoid arthritis

Registration

-  **Menveo** (conjugated liquid formulation) MenACWY

Key

-  Addition to pipeline
-  Deletion from pipeline due to approval or termination
-  Progressed to new Phase

*Asset returned to Research, termination for indication only

Performance: full-year outlook considerations to support modelling

Specialty Medicines turnover

Increase low double-digit % for Specialty, excluding Xevudy sales

Previous: increase approximately 10%

HIV to increase high single-digit %

Previous: mid to high single-digit

Turnover to Adjusted OP items

COGS: to increase at a rate below turnover

SG&A: to increase at a rate above turnover

R&D: to increase at a rate below turnover

The above items exclude the impact of COVID-19 solutions

Vaccines turnover

Increase mid to high-teens %, excluding pandemic adjuvant sales

Previous: increase low to mid-teens %

Shingrix to deliver record year for sales, with strong double-digit growth; *Shingrix* Q4 growth rate expected to be lower than prior quarters
Flu sales slightly down compared to 2021
Meningitis to increase around 10%
Established Vaccines expected to be broadly flat to slight decrease

Adjusted OP to Adjusted EPS items

Interest: between £700m to £750m

Previous: between £750m to £800m

Share of associates: negligible

Tax rate: around 17%, expect slightly higher in Q4.

Medium-term outlook around 16%

Previous: tax rate around 16%, similar to 2021 for GSK and aligned to medium-term outlook

Non-controlling interest: ViiV is main ongoing NCI

GSK Adj. EPS is expected grow around 1% less than Adj. OP

General Medicines turnover

Broadly flat

Previous: slight decrease

COVID-19 solutions

The majority of expected COVID-19 solutions sales for 2022 have been achieved YTD (£2.2bn). We now expect this to reduce overall GSK Adj. OP growth by around 4 percentage points.

Previous: between 4 to 6 percentage points.

Dividend

Expect 27.5p in H2 2022 for GSK (equivalent to 22p per share before the GSK share consolidation on 18 July 2022)

All turnover and growth comments at CER. All expectations and targets regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on page 67 of our third quarter 2022 earnings release, page 2 of our third quarter earnings release and the cautionary statement slide included with this presentation. Tax rate expectation is based on enacted legislation and is reflective of the anticipated performance of the business and key assets. The tax rate could fluctuate in individual years due to the timings of settlements of open years with tax authorities, as we continuously bring our tax affairs up to date. Interest expectation assumes no significant adverse movements in interest rates.

Performance: continuing operations basis for 2022 guidance

Historical financials, adjusted results

	2021					2022		
	Q1	Q2	Q3	Q4	FY	Q1	Q2	Q3
Including COVID-19 solutions								
Sales (£m)	5,155	5,838	6,627	7,076	24,696	7,190	6,929	7,829
Operating profit (£m)	1,325	1,641	2,209	1,317	6,492	1,943	2,008	2,605
Earnings per share (pence) pre-share consolidation	16.9	22.6	29.9	18.8	88.2	25.8	n/a	n/a
Earnings per share (pence) post-share consolidation	21.1	28.2	37.4	23.6	110.3	32.3	34.7	46.9
COVID-19 solutions impact								
Sales	-	276	209	920	1,405	1,307	466	417
Operating profit	(12)	233	97	214	532	194	58	141
Earnings per share (pence) pre-share consolidation	(0.2)	3.8	1.5	3.8	8.8	3.2	n/a	n/a
Earnings per share (pence) post-share consolidation	(0.3)	4.7	1.9	4.7	11.0	4.1	1.2	2.9

If exchange rates were to hold at the closing rates on 30 September 2022 (\$1.11/£1, €1.13/£1 and Yen 160/£1) for the rest of 2022, the estimated positive impact on 2022 Sterling turnover growth for GSK would be 7% and if exchange gains or losses were recognised at the same level as in 2021, the estimated positive impact on 2022 Sterling Adjusted Operating Profit growth for GSK would be 13%.

Performance: currency

2021 currency sales exposure¹

US \$ 49%

Euro € 19%

Japanese ¥ 6%

Other² 26%

2022 adj. operating profit

US \$: 10 cents movement in the average exchange rate for full-year impacts adj. operating profit by approx. +/- 7.0%

Euro €: 10 cents movement in the average exchange rate for full-year impacts adj. operating profit by approx. +/- 0.5%

Japanese ¥: 10 Yen movement in the average exchange rate for full-year impacts adj. operating profit by approx. +/- 1.0%

1. Based on 2021 GSK Group (as it was in 2021) sales excluding Consumer Healthcare, 2. The other currencies that each represent more than 1% of GSK sales include Australian Dollar, Brazilian Real, Canadian Dollar, Chinese Yuan and Indian Rupee. In total, they accounted for 11% of GSK revenues in 2021. If exchange rates were to hold at the closing rates on 30 September 2022 (\$1.11/£1, €1.13/£1 and Yen 160/£1) for the rest of 2022, the estimated positive impact on 2022 Sterling turnover growth for GSK would be 7% and if exchange gains or losses were recognised at the same level as in 2021, the estimated positive impact on 2022 Sterling Adjusted Operating Profit growth for GSK would be 13%.

Performance: robust capital allocation framework unchanged

Strengthened balance sheet supports priorities

Research & Development (including BD)

Continued investment in innovation and productivity

Value creating bolt-on acquisitions and strategic collaborations to strengthen the pipeline

SG&A (Commercial excellence, customer/patient facing)

Product launches, data & analytics, competitive intelligence, customer and patient insights

Capital expenditure (Sustainability and productivity)

£1-1.5bn capital projects, focus on technology platforms, supply chain network, sustainability

Dividends

Progressive dividend policy, 40% to 60% EPS pay-out ratio

GSK